Loading chat...
CA AB1288
Bill
Status
Vetoed
10/8/2023
Primary Sponsor
Anthony Rendon
Click for details
AI Summary
- Prohibits health care service plans from requiring prior authorization or step therapy for naloxone products, other FDA-approved opioid antagonists, buprenorphine, methadone, or long-acting injectable naltrexone used for substance use disorder treatment
- Prohibits health insurers from requiring prior authorization or step therapy for the same medications and products listed above
- Applies these restrictions notwithstanding any other law, effectively overriding existing medical management practices for these specific treatments
- Enacted September 11, 2023, after passing the Senate on September 5, 2023 and the Assembly on September 7, 2023
Legislative Description
Health care coverage: Medication-assisted treatment.
Last Action
Consideration of Governor's veto stricken from file.
1/25/2024
Committee Referrals
Appropriations7/13/2023
Health5/31/2023
Rules5/18/2023
Appropriations4/26/2023
Health3/2/2023
Full Bill Text
No bill text available